Loading...
Loading...
Browse drug and medication recalls including prescription drugs, OTC medications, and supplements. Stay informed about pharmaceutical safety alerts.
This recall involves Mindbodygreen Ultimate Multivitamin+ dietary supplement bottles with the following UPC, lot numbers and manufacturing dates (Month/Year format). The dietary supplements come in eight-ounce amber glass bottles with black caps, each containing 60 capsules. The UPC, lot numbers and manufacturing dates are printed on the bottle. UPC Lot Number Manufacturing Date 850027975177 0515I1 09/2021 0130B2 01/2022 0187I2 08/2022 0324J2 10/2022 0309A3 12/2022 0368L2 12/2022 0272B3 02/2023 850027975429 0408H3 06/2023 0143A4 12/2023 0179C4 02/2024 4021131 05/2024 4033211 07/2024 4080841 10/2024 A010611 03/2025 A021211 03/2025
This recall involves Mamisan Pain Relieving Topical Ointment jars. The ointment comes in an orange container with a white continuous thread lid and has the Mamisan trademark printed on top of the lid and on the label. The ointment was sold in a 3.52 ounce plastic jar. The wraparound label includes instructions and drug facts. Only jars with UPC code 860006498115 are included in the recall.
Presence of particulate matter: potential presence of metal particulates in the product.
Presence of particulate matter: potential presence of metal particulates in the product.
Failed Impurity/Degradation specifications: OOS results obtained at the 18-month timepoint
Subpotent product:out of specification assay results observed during long term stability testing.
Subpotent product:out of specification assay results observed during long term stability testing.
Presence of Foreign Tablets/Capsules
Correct Labeled Product Mispack-Size stated on carton label did not match the size of the bottle in the carton.
Subpotent product:out of specification assay results observed during long term stability testing.
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe
Unapproved drug claims on product labeling and product misbranded due to no Supplement Facts label
Unapproved drug claims on product labeling and product misbranded due to no Supplement Facts label
Unapproved drug claims on product labeling and product misbranded due to no Supplement Facts label
Unapproved drug claims on product labeling and product misbranded due to no Supplement Facts label
Cross Contamination with Other Products
Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.